Results 101 to 110 of about 5,939 (158)

Longitudinal Response Trajectories with Dupilumab or Upadacitinib in Moderate-to-Severe Atopic Dermatitis: A Multicentre Real-World Study: IL-AD (Italian Landscape Atopic Dermatitis). [PDF]

Dermatol Ther (Heidelb)
Potestio L, Patruno C, Ferrucci SM, Narcisi A, Ortoncelli M, Pezzolo E, Malagoli P, Girolomoni G, Guanti MB, Rossi M, Carugno A, Gola M, Satolli F, Loconsole F, Manzo Margiotta F, Balato A, Nettis E, Burroni AG, Rongioletti F, Savoia P, Veronese F, Dal Bello G, Paolino G, Esposito M, Legori A, Campanati A, Barei F, Zussino M, Gargiulo L, Bianco M, Ingurgio RC, Gaiani F, Maurelli M, Zerbinati N, Mercuri SR, Italian AD-Landscape Group, Ribero S, di Vico F, Napolitano M.   +38 more
europepmc   +1 more source

Treatment outcomes of prolonged induction or re-escalation dosing of upadacitinib in patients with inflammatory bowel disease. [PDF]

Crohns Colitis 360
Axenfeld E, Chaudhary V, Clinton JW, Frohlinger M, George L, Cross RK, Axelrad JE.   +6 more
europepmc   +1 more source

A Real-World Study of Upadacitinib in Anti-TNF Refractory Crohn's Disease: Effectiveness, Persistence, and Safety. [PDF]

J Inflamm Res
Fang Y, Zhou L, Li L, Zhang L, Zhu N, Hu J, Liu Q, Wu J, Zhang P, Mei Q, Han W.   +10 more
europepmc   +1 more source

Case Report: Rapid improvement with upadacitinib in a case of paradoxical skin lesions associated with SAPHO syndrome. [PDF]

Front Immunol
Du J, Gao Y, Geng S, Li C, Shang S.
europepmc   +1 more source

Real-world efficacy of oral upadacitinib for vitiligo and factors associated with treatment response: A retrospective study. [PDF]

JAAD Int
Liu Y, Shi X, Yuan Y, Sun R, Du J, Wang F, Ding X.   +6 more
europepmc   +1 more source

Comparative Effectiveness and Safety of Tofacitinib, Filgotinib, and Upadacitinib in Ulcerative Colitis: A Multicenter Real-World Cohort Study. [PDF]

Adv Ther
Tursi A, Pasta A, Elisei W, Barberio B, Mocci G, Savarino EV, de Barba C, Maconi G, Cataletti G, Scaldaferri F, Napolitano D, Costa F, Ceccarelli L, Marzo M, Monterubbianesi R, di Fonzo M, Lombardi G, Patturelli M, Ribaldone DG, Bertani L, Rodino' S, Sebkova L, Bodini G, Pranzo G, Serio M, Scarcelli A, Luppino I, Ferronato A, Spagnuolo R, Luzza F, Morano D, Gravina AG, Pellegrino R, Vespere G, Sedda S, Allegretta L, Fanigliulo L, Grossi L, Cortellini F, Forti G, Neve V, Piergallini S, Scarozza P, Bevevino G, Iacopini F, Capone P, Gaiani F, Kayali S, Mucherino C, D'antonio E, D'ascoli B, Colucci R, Bachetti F, Giorgetti GM, Clemente V, Pagnini C, Cuomo A, Donnarumma L, Onidi FM, Satta PU, Picchio M, Papa A, Italian Network for Inflammatory Bowel Diseases (IN-IBD).   +62 more
europepmc   +1 more source

Clinical outcomes of upadacitinib dose escalation in inflammatory bowel disease: A single-center retrospective cohort study. [PDF]

World J Gastrointest Pharmacol Ther
Ellington AL, Rambuss D, Barbina S, Chitnavis M.   +3 more
europepmc   +1 more source

Upadacitinib therapy for foreign body granuloma induced by facial fillers. [PDF]

An Bras Dermatol
Duan M, Wu Y, Shen H, Dai Y.
europepmc   +1 more source

Indirect inhibition of the NLRP3-interleukin-1β axis contributes to the efficacy of JAK1 inhibitors in experimental colitis and human ulcerative colitis. [PDF]

Nat Commun
Liu B, Spalinger MR, Invernizzi A, Gerdes E, Steglich B, Schwarzfischer M, Machicote A, Pelczar P, Pöhlmann D, Nawrocki M, Böttcher M, Aleko A, Velasquez LN, Wende S, Stallbaum F, Neuendorff J, Grosshauser S, Muscate F, Douilhet G, Perez LG, Sabihi M, Möller K, Viehweger F, Sutter JP, Kilian C, Kumar Y, Fründt T, Sauter G, Rösch T, Gagliani N, Caflisch A, Scharl M, Huber S.   +32 more
europepmc   +1 more source

Real-World Efficacy and Safety of Upadacitinib in Korean Patients With Atopic Dermatitis. [PDF]

Allergy Asthma Immunol Res
Park SY, Heo SJ, Gwag HE, Hong N, Kook HD, Jung HJ, Park MY, Ahn J.   +7 more
europepmc   +1 more source